Physician profile
Benjamin Boswell
NPI 1174958961
$4,177.35
in general payments reported to CMS, 2019-2025
14 companies · $304 in 2025
The $304 reported for 2025 was more than what 76% of Sports Medicine (Emergency Medicine) providers received nationally (typical 2025 total: $100).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $63.77 · 2021: $1,648 · 2022: $33.82 · 2023: $865 · 2024: $948 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $617.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,515.00 | 2021 | |
| Trice Medical, INC. | $1,500.00 | 2023-2024 | |
| Pacira Pharmaceuticals Incorporated | $234.75 | 2023-2025 | Iovera, Exparel, Zilretta |
| Djo, LLC | $206.00 | 2023-2025 | Chattanooga, Procare, Aircast |
| Bioventus LLC | $157.14 | 2020-2025 | Durolane, Durolane |
| Stryker Corporation | $155.62 | 2019-2023 | Variax, T2 |
| Pacira Therapeutics, INC. | $103.67 | 2019-2021 | |
| Horizon Therapeutics Plc | $93.87 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $58.42 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $40.34 | 2022-2024 | Uzedy |
| Rock Medical Orthopedics, INC. | $37.00 | 2021 | |
| Tenex Health INC. | $36.17 | 2019 | |
| Csl Behring | $24.19 | 2025 | Kcentra |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Boswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.